RepliCel Life Sciences Inc.

RepliCel Life Sciences Inc. is leading a revolution in the development of products for sports medicine and aesthetics. We are a regenerative medicine company developing innovative, clinical-stage technologies for unparalleled skin rejuvenation, tendon regeneration, and hair regrowth. RepliCel is currently involved in three clinical development programs: RCT-01 for treatment of Achilles tendinosis, RCS-01 for skin rejuvenation, and RCH-01 for treatment of Androgenic Alopecia. In Asia, RCH-01 is the subject of a co-development partnership with cosmetics and skincare giant Shiseido Company, Limited. Shiseido is currently funding a clinical study for the treatment of male and female pattern baldness (androgenic alopecia) in Japan with data anticipated in late 2018. RepliCel's nearest-term commercial asset is its next-generation dermal injector, RCI-02 which represents a medical device bringing unparalleled precision and consistency to dermal injections including shallow, even dispersion of dermal fillers for fine wrinkles. RCI-02 also promises to obviate the need for local anesthetic injections due to its patented skin-numbing element embedded in the device.